Table 1.
With aberration (N=16) | Without aberration (N=57) | ||||
---|---|---|---|---|---|
N | % | N | % | P | |
Patient-related | |||||
Age, years | 0.17 | ||||
<10 | 4 | 25.0% | 27 | 47.4% | |
10-<20 | 9 | 56.3% | 26 | 45.6% | |
20 or older | 3 | 18.8% | 4 | 7.0% | |
Race | 0.27 | ||||
Caucasian | 15 | 93.8% | 45 | 78.9% | |
Other | 1 | 6.3% | 12 | 21.1% | |
Karnofsky Performance Score1 | 0.07 | ||||
10–80 | 4 | 25.0% | 4 | 7.1% | |
90–100 | 12 | 75.0% | 52 | 92.9% | |
Transplant-related | |||||
Months from SAA diagnosis to HCT2 | 0.32 | ||||
<36 | 4 | 30.8% | 24 | 42.1% | |
36-<72 | 3 | 23.1% | 19 | 33.3% | |
≥72 months | 6 | 46.2% | 14 | 24.6% | |
Graft type, Bone marrow | 15 | 93.8% | 48 | 84.2% | 0.44 |
Conditioning regimen | 0.44 | ||||
Myeloablative | 7 | 43.8% | 16 | 28.1% | |
Reduced intensity/Nonmyeloablative | 9 | 56.3% | 38 | 66.7% | |
Other | 0 | 0% | 3 | 5.3% | |
GvHD prophylaxis | 0.68 | ||||
Ex vivo T-cell depletion | 10 | 62.5% | 35 | 61.4% | |
Tacrolimus-based | 1 | 6.3% | 2 | 3.5% | |
CSA-based | 4 | 25.0% | 18 | 31.6% | |
Others | 1 | 6.3% | 2 | 3.5% | |
Number of HLA matches | 0.81 | ||||
8/8 | 7 | 43.8% | 23 | 40.4% | |
≤7/8 | 9 | 56.3% | 34 | 59.6% | |
Year of transplant | 0.76 | ||||
1991–1999 | 8 | 50.0% | 26 | 45.6% | |
2000–2007 | 8 | 50.0% | 31 | 54.4% |
1 missing
3 missing